BioSpace54m
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
BioSpace1h
Aligos Claims Mid-Stage Win in MASH, But Investors Are Skeptical
An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...
BioSpace14h
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
BioSpace23h
After Fed Rate Cut, Biotech Stocks Face ‘Anticlimactic’ Reality
The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...